Acadia Pharmaceuticals Inc (ACAD) financials
Acadia Pharmaceuticals revenue and earnings by year
Acadia Pharmaceuticals's revenue was $1.07 billion in the fiscal year to December 31, 2025, up 11.9% from the year before. Net income was $391 million, 36.5% of revenue. Since the fiscal year to December 31, 2016, revenue has grown 58.1% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 10 fiscal years
| Fiscal year to | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.07 | 0.96 | 0.73 | 0.52 | 0.48 | 0.44 | 0.34 | 0.22 | 0.12 | 0.02 |
| Revenue growth | 11.9% | 31.8% | 40.4% | 6.8% | 9.6% | 30.3% | 51.5% | 79.2% | 620.7% | — |
| Gross profit | 0.98 | 0.88 | 0.68 | 0.51 | 0.47 | 0.43 | 0.33 | 0.21 | 0.12 | 0.01 |
| Gross margin | 91.7% | 91.5% | 94.3% | 98.0% | 96.0% | 97.7% | 96.7% | 94.5% | 92.7% | 82.3% |
| Operating income | 0.10 | 0.23 | -0.07 | -0.22 | -0.17 | -0.29 | -0.25 | -0.25 | -0.29 | -0.27 |
| Operating margin | 9.8% | 24.1% | -10.1% | -43.2% | -35.2% | -64.9% | -72.7% | -110.6% | -234.1% | -1574.1% |
| Net income | 0.39 | 0.23 | -0.06 | -0.22 | -0.17 | -0.28 | -0.24 | -0.25 | -0.29 | -0.27 |
| Net margin | 36.5% | 23.6% | -8.4% | -41.8% | -34.7% | -63.7% | -69.4% | -109.6% | -231.7% | -1565.9% |
| Diluted EPS | $2.30 | $1.36 | -$0.38 | -$1.34 | -$1.05 | -$1.80 | -$1.60 | -$1.95 | -$2.35 | -$2.34 |
| Free cash flow | 0.11 | 0.16 | 0.02 | -0.11 | -0.13 | -0.14 | -0.15 | -0.17 | -0.22 | -0.21 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open ACAD in Markets.
See also: ACAD valuation and P/E history · ACAD returns
No forecast, no recommendation. This page describes Acadia Pharmaceuticals Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.